文献速递前列腺增生与排尿功能障碍

他汀类药物使用与下尿路症状发生及进展:REDUCE试验事后分析

Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
PubMed 文献 · J Urol · 2021-09-21

REDUCE试验事后分析纳入3060例无症状(IPSS<8)和2198例有症状(IPSS≥8)男性,评估基线他汀使用与下尿路症状(LUTS)发生或进展的关联。多变量Cox回归显示,他汀使用与无症状男性LUTS发生(HR 1.05;95%CI 0.78-1.41,p=0.74)及有症状男性LUTS进展(HR 1.13;95%CI 0.96-1.33,p=0.15)均无显著关联。结论不支持他汀用于LUTS的预防或管理。

要点

  • 他汀使用与无症状男性LUTS发生风险无显著关联(HR 1.05,p=0.74)。
  • 他汀使用与有症状男性LUTS进展风险无显著关联(HR 1.13,p=0.15)。
  • 按治疗分组(度他雄胺/安慰剂)分层后结果相似。

核心结论

  • 在REDUCE试验中,他汀使用与无症状男性LUTS发生或有症状男性LUTS进展均无显著关联。
  • 数据不支持他汀在LUTS预防或管理中的作用。

研究设计与样本

  • REDUCE试验的事后分析,纳入3060例基线IPSS<8的无症状男性和2198例基线IPSS≥8且未使用α受体阻滞剂或5α还原酶抑制剂的有症状男性。
  • 采用多变量Cox回归模型评估基线他汀使用与LUTS发生及进展的关联。

主要发现

  • 无症状男性中550例(18%)使用他汀,有症状男性中392例(18%)使用他汀。
  • 无症状男性中,他汀使用与LUTS发生无显著关联(HR 1.05;95%CI 0.78-1.41,p=0.74)。
  • 有症状男性中,他汀使用与LUTS进展无显著关联(HR 1.13;95%CI 0.96-1.33,p=0.15)。
  • 按治疗分组(度他雄胺或安慰剂)分层后结果相似。

关键数值与推荐

  • 无症状男性LUTS发生定义为首次因BPH接受药物或手术治疗,或持续临床显著LUTS(连续2次IPSS>14)。
  • 有症状男性LUTS进展定义为IPSS较基线增加≥4分、因BPH接受任何手术或启动BPH药物治疗。

临床怎么用

  • 不应基于REDUCE数据将他汀用于LUTS的预防或管理。
  • 他汀使用与否不影响对BPH/LUTS患者症状发生或进展的评估。

局限性

  • 本研究为REDUCE试验的事后分析。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Benign prostatic hyperplasia (BPH) is a common disease often manifested by lower urinary tract symptoms (LUTS). We previously found statins were associated with modest attenuations in prostate growth over time in REDUCE. We tested whether statins were associated with LUTS incidence in asymptomatic men and LUTS progression in symptomatic men. MATERIALS AND METHODS: We performed a post-hoc analysis of REDUCE in 3,060 "asymptomatic" men with baseline International Prostate Symptom Score (IPSS) <8 and in 2,198 symptomatic men with baseline IPSS ≥8 not taking α-blockers or 5α-reductase inhibitors. We used multivariable Cox regression models to assess associations between statin use at baseline and LUTS incidence and progression. Among asymptomatic men, incident LUTS was defined as the first reported medical or surgical treatment for BPH or sustained clinically significant LUTS (2 reports of IPSS >14). Among symptomatic men, LUTS progression was defined as IPSS increase ≥4 points from baseline, any surgical procedure for BPH, or initiation of a BPH drug. RESULTS: Among asymptomatic and symptomatic men, 550 (18%) and 392 (18%) used statins at baseline, respectively. On multivariable analysis, statin use was not associated with LUTS incidence (HR 1.05; 95% CI 0.78-1.41, p=0.74) in asymptomatic men, or with LUTS progression (HR 1.13; 95% CI 0.96-1.33, p=0.15) in symptomatic men. Similar results were seen in the dutasteride and placebo arms when stratified by treatment assignment. CONCLUSIONS: In REDUCE, statin use was not associated with either incident LUTS in asymptomatic men or LUTS progression in symptomatic men. These data do not support a role for statins in LUTS prevention or management.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kramer JJ, Gu L, Moreira D, et al. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. J Urol. 2021. PMID: 34544265. doi:10.1097/JU.0000000000002199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。